Introduction
Colorectal cancer is a common cancer worldwide, and early detection is essential for better treatment outcomes. COLOTECTTM CRC Screening analyzes stool samples for specific DNA markers that indicate colorectal cancer or precancerous polyps. It offers a convenient and patient-friendly option, allowing for early detection without the discomfort or preparation required by traditional screening methods.
What clinical challenges are targeted by COLOTECT™ CRC Screening
In clinical practice, many patients hesitate to undergo colonoscopy due to concerns about discomfort, complex preparation, or fear of the invasive procedure. This reluctance results in low screening compliance, hindering early detection of colorectal cancer (CRC), which is critical for improving survival rates.
Stool-based biomarker tests offer a non-invasive alternative for CRC screening. These tests detect DNA methylation changes commonly seen in cancerous and precancerous cells, present in stool samples. By identifying these biomarkers, stool-based tests provide valuable insights for early detection and can guide further diagnostic steps, addressing the challenge of low adherence to traditional screening methods.
Applicable Clinical Scenarios
- Individuals over 45 years old.
- Individuals with a family history of colorectal cancer, which increases risk due to genetic factors, particularly among first-degree relatives diagnosed with CRC.
- Individuals with unhealthy lifestyle habits, such as high intake of red and processed meat, smoking, and heavy drinking.
- Individuals who are overweight or obese.
- Individuals diagnosed with type II diabetes, as confirmed by a healthcare provider or through a diabetes association.
Important features of COLOTECT™ CRC Screening
Product Name | COLOTECTTM CRC Screening |
Detection Method | Methylation-Specific qPCR / Methylation-Specific qPCR + Fecal Immunochemical Test |
Option 1 | COLOTECTTM CRC Screening 1.0 (DNA Methylation Detection for Human SDC2, ADHFE1 and PPP2R5C Genes) |
Option 2 | COLOTECTTM CRC Screening 3.0 (Combined Detection Kit for Human ADHFE1/OPLAH Genes Methylation and Fecal Occult Blood) |
Sample Type | Stool Sample |
Why choose COLOTECT™CRC Screening
- Private and Convenient
The sample collection process is private and convenient for customers. - Non-invasive and Painless
The test uses stool samples without requiring bowel preparation, making it non-invasive and painless. - Comprehensive Detection Method
The Multi-biomarker offers a comprehensive method for detecting colorectal cancer and pre-cancerous lesions. - Total Solution
BGI Genomics provides a total solution with COLOTECT™ 1.0/3.0, covering the entire process from sample collection to laboratory processing.
The COLOTECT™ CRC Screening
Step 1
Physician orders test
Step 2
Sample collected
Step 3
Sample shipped to us and analyzed
Step 4
Results sent to physician
Step 1
Physician orders test
Step 2
Sample collected
Step 3
Sample shipped to us and analyzed
Step 4
Results sent to physician
Localization solution of COLOTECT™ CRC Screening
Automated Nucleic Acid Extraction | Methylation Detection | Bioinformatics Analysis | ||
---|---|---|---|---|
Equipments | Throughput | Equipments | Throughput | |
NE-384 | 96-384 samples/run | Slan-96S | 92 samples/run | Halos |
Purifier HT | 96 samples/run | Bioer 9600 | 92 samples/run | |
Purifier 32 | 32 samples/run | Quant Studio 5 | 92 samples/run |
- User-friendly control
User-friendly with high automation, enabling quick and efficient handling of large sample volumes.
- Accurate detection
Automated DNA extraction and detection process, combined with advanced bioinformatics for accurate and comprehensive results
- Flexible throughput
Metagenomic sequencing of 32-384 samples can be performed at a time depending on different platforms
- Convenient and fast
For localized operation, TAT time from sample processing to obtaining report is within 24 hours
COLOTECT™ CRC Screening Resources
Learn more about our product solution by downloading our relevant materials.